Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612626 | 0.89 | POLB (0.50) | AOC3KCNQ2LMNAHSD17B10POLB | |
| SCHEMBL19612637 | 0.87 | ASAH1 (0.46) | KCNQ2LMNAHSD17B10POLBALDH1A1 | |
| SCHEMBL7432230 | 0.86 | ASAH1 (0.48) | POLBALDH1A1 | |
| SCHEMBL19612571 | 0.86 | ASAH1 (0.48) | POLBALDH1A1 | |
| SCHEMBL28718558 | 0.85 | CYP2C19 (0.46) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL582647 | 0.84 | LMNA (0.56) | KCNQ2LMNAHSD17B10POLBALDH1A1 | |
| SCHEMBL16820449 | 0.84 | LMNA (0.56) | KCNQ2LMNAHSD17B10POLBALDH1A1 | |
| SCHEMBL6410341 | 0.84 | LMNA (0.56) | KCNQ2LMNAHSD17B10POLBALDH1A1 | |
| SCHEMBL19228532 | 0.84 | CYP2C19 (0.53) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL643461 | 0.84 | CYP2C19 (0.53) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009285-A1 | PRE-SEIZURE DETECTION DEVICE INCORPORATING ELECTRONIC NOSE TECHNOLOGY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2025-01-09 | — | — | US | disclosed |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | XIAMEN UNIVERSITY (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| CN-102105436-B | Oral fatty acid derivatives endowed with high palatability | BERNI CANANI ROBERTO | 2014-11-12 | — | — | CN | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| EP-1695955-B1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| CN-102105436-A | Oral fatty acid derivatives endowed with high palatability | ROBERTO BERNI CANANI | 2011-06-22 | — | — | CN | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1695955-A1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6127426-A | ANTIALLERGIC AND -INFLAMMATORY AGENTS E.G., TREATING PSORIASIS, BLOCKED ON THE C-10 BY A NONPHENOLIC ARYLACYL OR A PHENYLALKYLIDENE GROUP; LIPOXYGENASE INHIBITORS; ANTIPROLIFERATIVE AGENTS; LOW DOSAGE; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-10-03 | — | — | US | disclosed |
| EP-0664780-B1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMA (IL) | 1999-12-08 | — | — | EP | disclosed |
| US-5952390-A | ANTIINFLAMMATORY AGENTS; TREATMENT FOR PSORIASIS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-09-14 | — | — | US | disclosed |
| US-5844004-A | 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceuticals | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-12-01 | — | — | US | disclosed |
| US-5661187-A | ADMINISTERING TO TREAT AN ALLERGIC OR INFLAMMATORY CONDITION; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-08-26 | — | — | US | disclosed |
| EP-0664780-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-02 | — | — | EP | disclosed |
| US-5426197-A | Antiinflammatory, antiallergy or antitumor agents | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | CYP2C19 938/4885CYP1A2 1236/4885CYP3A4 679/4885 |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | FAAH, NAAA, FAAH2 | CYP2C19 252/4885CYP1A2 286/4885CYP3A4 407/4885 |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | LPAR2, LPAR1, LPAR5 | CYP2C19 4847/4885CYP1A2 4018/4885CYP3A4 4859/4885 |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | DHPS, CYP3A5, CYP3A4 | CYP2C19 21/4885CYP1A2 9/4885CYP3A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.